laboratori corp america hold lh nyse qqq
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jun
estim may
price data jun
rate updat jun
currenc amount express
valuat growth profit
methodolog valu compani
particip highli attract duopoli offer bright
prospect healthcar move toward reform payment model
even though hospit still domin billion diagnost
market labcorp carv signific slice pie
serial acquisit addit covanc drug-develop
expertis offer labcorp avenu monet larg patient
labcorp continu acquir smaller rival strategi
paid firm firm grow anticip cost
structur becom even competit attract
larg managed-car payer increas
importantli labcorp single-mindedli pursu greater
effici translat abil reduc cost
quickli reimburs cut come pike firm
invest greater autom system decreas
number employe involv sort run test
labcorp also put signific resourc behind beef
inform technolog capabl result physician
easili access test inform time manner
patient schedul blood draw increas conveni
admir manag team consist focus
strategi long term expect labcorp
invest today reap reward futur year
labcorp take advantag long-term secular trend
bode well diagnost industri prolifer
new test grow new diseas marker genet mutat
pharmacogenom
implic discov new
reimburs model inspir healthcar reform lead
doctor hospit send test lower-cost produc
like labcorp though util hit soft
period thank recessionari condit volum turn corner
financi stress eas new insur join
roll labcorp also sought enhanc abil find
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
nation second-largest
laboratori corpor america
independ clinic laboratori roughli independ lab
market compani oper patient-servic center
offer broad rang clinic lab test rang routin blood
urin screen complex oncolog genom test addit
covanc labcorp also sizabl footprint global contract
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
valuat growth profit jun
hold steadi fair valu estim per
share continu expect robust growth drug
develop busi sustain four
consecut quarter growth addit chiltern
give labcorp greater footprint small medium
size biopharma area assum new medicar clinic
lab fee schedul adjust greater impact
taper estim
top-lin growth averag annual follow
five year near term anticip volum growth
solidifi thank increas healthcar util
gradual transit bundl capit
keep long-term trend anticip
increas growth genom esoter test compar
routin test labcorp done good job
launch new complex test lead us believ
annual esoter test volum outpac market growth
also think special test carri higher
price tag routin counterpart result averag
annual price increas long term
off-set reimburs pressur routin
test still make bulk labcorp test mix
think labcorp invest enlighten
covanc put firm strong posit take
advantag emerg opportun longer term
demonstr valu refer lab add beyond
deliveri reliabl accur test data anticip
acquisit add approxim per year total
think labcorp make
adjust oper
margin -- tune basi point -- time
base sole averag volatil cash flow
labcorp underli diagnost busi would rate
firm uncertainti medium howev assumpt
lower corpor tax rate base-cas bull
scenario along conserv project
fail tax reform bear case widen
uncertainti high
bull case valu share scenario
assum robust volum gain stronger-than-expect
price gain come implement pama rate
greater-than-anticip revenu synergi
combin labcorp patient databas
covanc clinic trial busi result adjust
annual top-lin growth higher
throughput assum labcorp enjoy greater oper
leverag translat gain
bearish scenario project sluggish volum growth
aca-rel fund ignor washington
number uninsur patient rise drug
develop segment fail reach histor growth level
also bake increas bad debt expens
estim oper margin fall basi
point next five year thank weak volum
tight price pressur bear labcorp case put
fair valu estim per share
labcorp narrow moat base vast nation
infrastructur translat consider scale
advantag smaller region lab independ
diagnost test industri primari test lab
patient-servic center across unit state
labcorp abl run test specimen day
substanti lower cost hospit
doctor offic smaller independ lab popul
market labcorp abil accommod higher
throughput extens use autom afford
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
entiti healthcar arena
think addit covanc solidifi labcorp
narrow moat -- previous award covanc narrow
moat right contract research organ
moatiest part busi late-stag clinic
trial global infrastructur critic easili
replic legaci covanc busi also benefit
intang asset includ expertis local countri
cultur regulatori agenc chang regul
research design data analyt knowledg key diseas
state close relationship pharmaceut
biotech client clinic trial busi tap
labcorp enorm patient databas order better
match elig patient appropri trial reduc
enrol time capabl give labcorp advantag
competit
see labcorp moat trend posit think labcorp
particularli well-posit take advantag
long-term opportun emerg wake
healthcar reform evolut volume-bas
value-bas reimburs payer assess valu
link chain patient diagnosi
treatment simultan widespread adopt
new digit tool manipul analyz patient data
two factor set stage diagnost
compani demonstr valu diagnost
test -- specif much time money save --
captur valu tradit gone
therapeut agent end-stag treatment new
avenu growth diagnost compani exist
healthcar reform push labcorp
quest new nonexclus contract
latest step closer collabor bring diagnost data
claim data togeth analyt use
see new growth prospect horizon
firm much lower cost structur -- significantli lower
hospit smaller independ lab
advantag also mean labcorp model character
substanti oper leverag oper leverag
work firm wake recess
healthcar util fell howev util
return growth labcorp also benefit though
addit cro busi pressur margin
although price ration recent past
potenti price competit keep us award
payer would typic rather negoti largest
refer lab includ labcorp provid best
geograph coverag insur base instead
cobbl togeth market-by-market coverag
multipl smaller region lab final labcorp scale
reach make attract partner research
invent variou diagnost test distribut
channel sell test labcorp recent
invest dedic lab focus companion
diagnost anoth indic firm think
creativ close partner
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
enlighten health busi put firm strong
posit key owner data line
final acquisit covanc expertis data
analyt clinic trial give labcorp big boost
capabl anticip labcorp find new
applic covanc compet tie diagnost
measur therapi patient outcom cost
diagnost compani abil ultim capit
depend well develop capabl beyond
current core compet logist lab qualiti
must develop new expertis data collect
integr well informat point think
labcorp pull ahead quest prepar
first labcorp alreadi laid groundwork
integr inform technolog platform --
first step toward possibl aggreg test data
second labcorp alreadi dip toe water
come informat challeng
measur cost save diagnost particular
think firm experi demonstr result
small-scal kidney stone manag chronic
kidney diseas monitor program give labcorp leg
competit futur expect see labcorp
target key diseas area early-detect
treatment monitor program could implement
provid cost save addit covanc late-stag
trial expertis boost labcorp abil conduct
third applaud labcorp savvi move launch new
enlighten genom unit firm initi
address immens potenti next-gener
sequenc although yet reach point
routin sequenc take place patient
question technolog alreadi shape
realm oncolog see applic heart
diseas central nervou system neurolog labcorp
busi build capabl area new
geneticist staff well specialist analyt
valu amass proprietari test
patient data labcorp alreadi detect trend
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
dissip impend
nonexclus relationship help labcorp navig
oit possibl industri lawsuit
human servic fail market-bas
rate medicar clinic lab fee schedul
oth complex labor-intens esoter test
reimburs higher rate often outsourc
hospit independ lab labcorp funnel
resourc broaden menu complex esoter
test help maintain healthi margin
olabcorp abl keep less profit
capit managed-car contract minimum
account diagnost revenu
olabcorp need analyt expertis covanc
would diminish labcorp retain
oit could take longer anticip bundl
payment becom norm provid
case increas volum ensu oper
leverag could five year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
acquisit covanc increas labcorp debt
leverag substanti fund acquisit earli
labcorp borrow five-year term loan may
prepaid without penalti billion new senior
unsecur note matur
end decemb labcorp debt stood
billion time ebitda time prior
acquisit howev end debt/ebitda
fallen time firm debt tick time
labcorp yet reach target ratio
time longer term comparison quest aim
low long run even slightli higher
higher cash level may keep net leverag
roughli line even slightli lower quest
long run addit million cash held
balanc sheet end estim
labcorp abl gener billion averag
annual free cash flow next five year
plenti help firm manag debt oblig
intern mean
base averag volatil cash flow labcorp
underli diagnost busi rate firm
uncertainti medium despit mani long-term clinic
undercurr favor labcorp see
potenti near-term bumpi sever great
recess spur declin patient volum across
specialti consum delay seek
healthcar especi nonacut nonsymptomat
condit seen gradual resumpt growth
patient traffic unfavor macro condit aris
labcorp volum could drop key measur
afford act dismantl could lead
less volum higher bad debt expens chang
reimburs penetr high-deduct plan
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
substanti cost-shar measur also left
patient larger out-of-pocket burden could
becom perenni drag growth diagnost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
repres date owner name posit common share held report holder issuer
new jersey divis pension benefit
govern pension fund norway global
share
fund
share
fund
assign standard stewardship rate labcorp david
king took role ceo earli follow
retir thoma mahon held posit
nearli decad brief transit period king also
took titl chairman think king prior
experi labcorp good foundat
core diagnost busi impress
king navig compani
increasingli competit industri landscap steep
volum well
unorthodox integr covanc clinic trial
busi king previou experi labcorp
corpor plan strateg develop function
also advantag perspect especi
consid firm on-going relianc acquisit
smaller lab opportun arisen
adjac area howev note labcorp
compens polici rel gener king
earn million past three year
one hand appreci king vision
understand healthcar system lurch
lab need adapt potenti move new line
busi think acquisit covanc reflect
king view simpli gener data longer enough
captur valu healthcar futur healthcar
competitor also compet basi proprietari
ownership data well abil translat
data usabl medic knowledg hand
think king tendenc appli great pressur
execut team could lead greater turnov may
prevent firm realiz potenti emerg
overal appreci manag execut
year firm maintain great major
contract payer provid custom even
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
rack new client sizabl empir
cross shield plan new york exclus
contract negoti rais
eyebrow time concern unfavor
price labcorp born importantli like
labcorp capital-alloc decis particular firm
exercis financi disciplin acquisit strategi
acquisit accret shortli close
firm avoid write goodwil although
labcorp pay dividend manag funnel
return sharehold form share buyback
applaud firm acceler repurchas share
trade discount
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
unitedhealth increas access low-cost diagnost
lab labcorp quest may
long-stand exclus contract labcorp
primari in-network diagnost lab final extinguish
announc would maintain
relationship labcorp also fulli bring
in-network start although
announc shift fair valu estim
three narrow-moat compani news
provid lift labcorp quest whose share
trade tightli around intrins valu
though possibl labcorp lose contract
hover lab firm last year
thought much like payer would
add quest mix rather replac labcorp quest
unlik last time exclus lab contract
exchang hand quest labcorp payer
far focus reduc use high-cost provid
otherwis known hospital-bas lab secur
lowest price possibl two lab competitor
alreadi lowest-cost produc industri
thank afford act particip
therapeut maker -- evolv align
interest around better health outcom effici
use resourc payer gotten seriou appli
carrot stick encourag provid move away
higher-cost hospital-bas lab increas access
lowest-cost option labcorp quest
unitedhealth strateg allianc
independ lab also mean gain access
diagnost test data real time allow payer move
closer point provid made actual
treatment decis anticip three firm
come new approach value-bas
reimburs lab
labcorp weather reimburs pressur thank
labcorp saw first-quart result amplifi acquisit
favor foreign exchang hold steadi
fair valu estim firm appear track
meet full-year project weve brace
neg impact pama cut
medicar clinic lab fee schedul took effect
januari saw littl quarter shift view
labcorp narrow econom moat continu think
firm well posit earn econom profit thank
scale cost structur consolid industri
separ posit impact paml acquisit
currenc tailwind pleas see strong
quarterli organ volum growth diagnost
segment element off-set declin
organ revenu growth due price test mix --
surmis decreas driven primarili cut
medic clf manag expect amount
million reduct revenu probabl
wont clearer view pama cut labcorp
get beyond anniversari paml acquisit may
thank addit chiltern john ratliff
leadership drug develop segment back track
quarterli book/bil remain robust bar
cancel manag expect convert roughli
billion next month weve impress
new tool labcorp develop marri
legaci covanc detail knowledg grassroot
aspect make trial enrol faster
convers slow enrol labcorp abil find
potenti trial particip patient databas
particular combin servic may enough
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
dislodg contract research organ giant iqvia
think would difficult smaller
includ parexel icon challeng labcorp
consid advantag iqvia labcorp
offer pharma biotech client surpris see
smaller band togeth cooper establish
open technolog standard trial sponsor
hope seem easier sponsor
work across particip eas less
like choos iqvia labcorp trial
view move tacit acknowledg among smaller
cro competit disadvantag
final continu believ on-going reimburs
pressur diagnost test ultim benefit
largest refer lab labcorp quest smaller
independ higher-cost hospit lab find
less abl compet howev hasnt
wholesal wave hospit put lab sale
seem consist trickl situat
especi hospit administr reassess
strateg valu lab labcorp quest
take advantag situat forg
differ type agreement hospit think
industri legal action pama rule may delay
decis lab hospit rule
expect sometim midyear court direct
center medicar medicaid overhaul
defin applic lab includ hospital-bas
lab could allevi reimburs pressur enough
convinc hospit hold test volum
labcorp cap strong perform
fourth quarter modestli exceed expect
weve rais fair valu estim per share
weve bump project higher growth
drug develop segment well
profit thank new cost effici account
slightli half increas valuat
half increas driven firm new lower
effect tax rate remain confid firm narrow
econom moat continu think labcorp weather
pama-rel cut medicar clinic lab fee
schedul midterm
even without top-lin boost acquisit
labcorp deliv respect underli growth
quarterli organ volum growth clock
consider stronger quest though
revenu per requisit soft addit chiltern
drug develop segment shore firm
presenc small medium size biopharma
area pleas see drug develop seen
four consecut quarter growth backlog net
industri lawsuit depart
human servic challeng medicar clf rate
set could take month resolv think
lab industri offer compel argument
process set rate particularli applic lab
defin cut alreadi implement
long thought rate cut would
longer term caus small independ hospital-
quest
labcorp consid difficulti hospit
isol lab profit could take number
quarter see flow test volum larg
shift volum
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
